Doctors Revision

Oral & Dental Health

Kaposi's Sarcoma (Oral)

A malignancy of vascular endothelial cells, strongly associated with Human Herpesvirus 8 (HHV-8) and often occurring in the context of immunosuppression, particularly HIV/AIDS. Oral lesions are common.

Also known as: KS Mouth

Open in the interactive guide
On this page

Referral and warning signs

When to refer

Refer ALL suspected cases of oral Kaposi's Sarcoma URGENTLY to a centre capable of biopsy and specialist management (Oral Medicine, Oncology, HIV clinic at H/RR/UCI).

Red flags

  • Purplish/red vascular lesion(s) on oral mucosa, especially palate or gingiva, in HIV+ or at-risk individual.
  • Rapidly growing or ulcerating oral lesion.
  • Associated skin lesions or systemic symptoms.

Signs and symptoms

  • Painless (usually) lesions on oral mucosa.
  • Appearance: Red, purple, or brown patches, plaques, or nodules.
  • Most common oral site: Hard palate.
  • Other sites: Gingiva, tongue, buccal mucosa.
  • Lesions may be flat or raised, solitary or multiple.
  • May ulcerate or bleed, especially on gingiva.
  • Can cause tooth mobility if involves gingiva extensively.
  • May be associated with skin lesions or involvement of other organs (lymph nodes, lungs, GI tract) in AIDS-related KS.

Risk factors

  • HIV infection / AIDS (especially with low CD4 count).
  • Human Herpesvirus 8 (HHV-8) infection (necessary cofactor).
  • Immunosuppression (e.g., post-transplant).
  • Endemic KS (older men of Mediterranean/Eastern European descent - less common).
  • African endemic KS (can occur independent of HIV).

Diagnosis

Clinical assessment

Suspicion based on characteristic appearance (purplish vascular lesion) in an at-risk individual (especially HIV+). Palate is classic location.

Differential diagnosis

  • Haemangioma / Vascular malformation.
  • Pyogenic granuloma.
  • Bacillary angiomatosis (in HIV).
  • Amalgam tattoo (gingiva).
  • Melanoma (pigmented lesion).
  • Lymphoma.
  • Gingival hyperplasia.
  • Periodontal abscess (if ulcerated/swollen gingival lesion).

Investigations

  • Biopsy: Incisional or excisional biopsy for histopathological confirmation is essential.
  • HIV testing (if status unknown).
  • CD4 count and Viral Load (if HIV+).
  • Staging workup (Chest X-ray, potentially CT scans) if systemic KS suspected.

Diagnostic criteria

Histopathological confirmation of Kaposi's Sarcoma from biopsy.

Management

Non-pharmacological management

  • Initiation or Optimization of Antiretroviral Therapy (ART): Mainstay of treatment for AIDS-related KS. Often leads to regression or stabilization of lesions.
  • Maintain good oral hygiene.

Pharmacological treatment

  • Requires Specialist Management (Oncologist/HIV Specialist/Oral Medicine): (LOC: RR/UCI)
  • Treatment depends on extent, location, symptoms, immune status, systemic involvement.
  • Local Therapies (for limited, symptomatic, or cosmetically sensitive lesions):
  • - Intralesional chemotherapy (e.g., Vinblastine).
  • - Cryotherapy.
  • - Laser ablation.
  • - Topical Alitretinoin gel.
  • - Radiation therapy (low dose).
  • Systemic Chemotherapy: Indicated for widespread, rapidly progressive, symptomatic, or visceral KS.
  • - Agents include: Liposomal Doxorubicin, Paclitaxel.

Monitoring

Monitor lesion size and number, symptoms. Monitor HIV status (CD4, Viral Load). Follow up with oncology/HIV specialist.

Complications

  • Bleeding.
  • Pain (if ulcerated).
  • Difficulty eating or speaking (large lesions).
  • Tooth mobility/loss (gingival involvement).
  • Psychosocial impact due to appearance.
  • Systemic spread.

Prevention

  • Effective Antiretroviral Therapy (ART) for HIV significantly reduces risk.
  • Safe sexual practices (may reduce HHV-8 transmission).

Patient education

  • Explanation of KS and its link to HHV-8 and immunosuppression (HIV).
  • Importance of ART adherence for AIDS-related KS.
  • Treatment options available.
  • Need for biopsy.
  • Oral hygiene importance.
  • Need for specialist follow-up.

Uganda-specific notes

Oral KS is a common AIDS-defining illness in Uganda. Hard palate is the most frequent site. Initiation/optimization of ART is the primary management strategy. Access to systemic chemotherapy and local therapies is limited to specialized centres.

References

  • Uganda Clinical Guidelines (UCG) 2023

    Chapter 23, Section 23.3.3

  • Uganda Clinical Guidelines (UCG) 2023

    Chapter 7 (HIV Care - OIs and Malignancies)

Scroll to Top